SNORA4: A Protein Involved in The Transfer of Sodium and Glucose Across The Blood-Brain Barrier

Target Name: SNORA4

NCBI ID: G619568

SNORA4

Other Name(s): ACA4 | Small nucleolar RNA, H/ACA box 4 | small nucleolar RNA, H/ACA box 4

SNORA4: A Protein Involved in The Transfer of Sodium and Glucose Across The Blood-Brain Barrier

SNORA4 (short for Sodium-Glucose cotransporter 4) is a protein that is expressed in the brain and is involved in the transport of both sodium and glucose across the blood-brain barrier. The brain is unique in its need for a constant supply of both of these essential nutrients, and the barrier that separates it from the rest of the body makes it difficult for substances to enter or exit the brain. SNORA4 plays a crucial role in maintaining the integrity of this barrier and is therefore of great interest as a potential drug target or biomarker.

The sodium-glucose cotransporter (SLC) is a family of transmembrane proteins that are responsible for transporting a variety of different substances across the membrane of the endothelium, including drugs, toxins, and diagnostic agents. SLCs are expressed in most tissues and play a vital role in maintaining homeostasis and the proper functioning of the body.

SNORA4 is a member of the SLC family and is expressed in the brain. It is involved in the transport of sodium and glucose across the blood-brain barrier, which is a specialized barrier that separates the brain from the rest of the body. The blood-brain barrier is designed to protect the brain from harmful substances, but it also makes it difficult for drugs and other substances to enter or exit the brain. SNORA4 helps to maintain the integrity of this barrier by transporting sodium and glucose across it.

SNORA4 is also involved in the regulation of the amount of sodium and glucose that enters and leaves the brain. It does this by controlling the amount of sodium and glucose that is released from the endothelium and by regulating the amount of sodium and glucose that is taken up by the brain. This helps to maintain a delicate balance of sodium and glucose in the brain and is essential for maintaining the health and function of the brain.

SNORA4 is also of interest as a potential drug target because it is involved in the transport of a variety of different substances across the blood-brain barrier. This means that drugs that are designed to interact with SNORA4 may be able to cross the barrier and affect the brain, potentially leading to therapeutic benefits. For example, drugs that are used to treat Alzheimer's disease have been shown to increase the expression of SNORA4 in the brain, which may help to improve the effectiveness of the drugs.

SNORA4 is also of interest as a potential biomarker for the diagnosis and treatment of certain neurological disorders. For example, altered levels of SNORA4 have been observed in the brains of individuals with Alzheimer's disease, which may be an indication of the severity of the disease. Additionally, studies have shown that SNORA4 levels are often reduced in the brains of individuals with other neurological disorders, such as Parkinson's disease and multiple sclerosis. These findings suggest that SNORA4 may be a useful biomarker for the diagnosis and treatment of certain neurological disorders.

In conclusion, SNORA4 is a protein that is expressed in the brain and is involved in the transport of sodium and glucose across the blood-brain barrier. It plays a crucial role in maintaining the integrity of this barrier and is therefore of great interest as a potential drug target or biomarker. Further research is needed to fully understand the role of SNORA4 in the brain and to develop effective treatments for the symptoms associated with SNORA4-related disorders.

Protein Name: Small Nucleolar RNA, H/ACA Box 4

The "SNORA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets